US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
EP2305027B1
(en)
*
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
AU777918B2
(en)
*
|
1997-05-05 |
2004-11-04 |
Amgen Fremont Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
EP1032674B1
(en)
|
1997-11-21 |
2007-01-24 |
Serono Genetics Institute S.A. |
(chlamydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
KR100769104B1
(ko)
|
1997-11-28 |
2007-10-23 |
세로노 제네틱스 인스티튜트 에스.에이. |
클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
|
WO1999062941A2
(en)
|
1998-06-01 |
1999-12-09 |
Urogenesys, Inc. |
Serpentine transmembrane antigens expressed in human cancers and uses thereof
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
ATE458008T1
(de)
|
1998-12-23 |
2010-03-15 |
Pfizer |
Humane monoklonale antikörper gegen ctla-4
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
JP4405686B2
(ja)
|
1999-03-09 |
2010-01-27 |
ザイモジェネティクス,インコーポレイティド |
新規サイトカインzalpha11リガンド
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2369413C
(en)
|
1999-04-12 |
2013-07-09 |
Agensys, Inc. |
Transmembrane protein expressed in prostate and other cancers
|
EP1792989A1
(en)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13 Transmembrane protein expressed in prostate cancer
|
DK2314315T3
(da)
|
1999-06-01 |
2015-02-02 |
Biogen Idec Inc |
Blokerende monoklonalt antistof for det humane alfa1-I-domæne af VLA-1 samt dettes anvendelse til behandling af inflammatoriske sygdomme
|
US6833268B1
(en)
*
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
ATE486938T1
(de)
|
1999-08-12 |
2010-11-15 |
Agensys Inc |
C-typ-lektin-transmembran-antigen, das in menschlichem prostatakrebs exprimiert wird, und verwendungen dieses antigens
|
KR20020047132A
(ko)
|
1999-08-24 |
2002-06-21 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
JP4272376B2
(ja)
|
1999-10-05 |
2009-06-03 |
アジェンシス,インコーポレイテッド |
前立腺ガンにおいてアップレギュレートされるgタンパク質結合レセプターおよびその使用
|
US6893818B1
(en)
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
EP2194130A1
(en)
|
1999-12-23 |
2010-06-09 |
ZymoGenetics, L.L.C. |
Cytokine ZCYTO18
|
MXPA02007756A
(es)
|
2000-02-10 |
2004-09-10 |
Abbott Lab |
Anticuerpos que aglutinan interleuqina-18 humana y metodos de fabricacion y uso.
|
WO2001077361A1
(en)
*
|
2000-04-10 |
2001-10-18 |
American Biogenetic Sciences, Inc. |
Human immunoglobulin-producing gnotobiotics
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
CA2412239C
(en)
|
2000-06-26 |
2013-05-28 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17
|
KR100919593B1
(ko)
|
2000-06-29 |
2009-09-29 |
아보트 러보러터리즈 |
이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
|
RU2292394C2
(ru)
|
2000-06-30 |
2007-01-27 |
ЗАЙМОДЖЕНЕТИКС, Инк., |
Интерферон-подобный белок zcyto21
|
EP1299727B1
(en)
|
2000-07-12 |
2009-04-22 |
Agensys, Inc. |
Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
|
CN1468250A
(zh)
*
|
2000-08-03 |
2004-01-14 |
��ķһ����˹��̹ |
在转基因动物中产生人源化抗体
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
AU8846601A
(en)
|
2000-08-28 |
2002-03-13 |
Agensys Inc |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
WO2002058717A2
(en)
|
2000-10-18 |
2002-08-01 |
Immunex Corporation |
Methods for treating rheumatoid arthritis using il-17 antagonists
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
DE60138832D1
(de)
|
2000-11-17 |
2009-07-09 |
Kyowa Hakko Kirin Co Ltd |
Expression xenogener (menschlicher) immunglobuline in geklonten, transgenen rindern
|
JP4434580B2
(ja)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
予防及び治療のために抗rsv抗体を投与/処方する方法
|
EP2336368A1
(en)
|
2000-12-07 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
JP2005505236A
(ja)
*
|
2000-12-19 |
2005-02-24 |
アルトー バイオサイエンス コーポレイション |
ヒト化免疫系を含むトランスジェニック動物
|
KR100830082B1
(ko)
|
2001-01-05 |
2008-05-20 |
화이자 인크. |
인슐린 유사 성장 인자 ι수용체에 대한 항체
|
WO2002064612A2
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US7795494B2
(en)
|
2001-03-22 |
2010-09-14 |
Abbott Laboratories |
Transgenic mice expressing antibodies specific for genes of interest and uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
EP1573024A4
(en)
|
2001-04-10 |
2007-08-29 |
Agensys Inc |
NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
CA2443903C
(en)
|
2001-04-13 |
2018-03-20 |
Biogen, Inc. |
Antibodies to vla-1
|
JP2005519580A
(ja)
|
2001-05-16 |
2005-07-07 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
非ヒト動物由来のヒト抗肺炎球菌抗体
|
PT1572874E
(pt)
|
2001-05-25 |
2013-12-11 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente aos receptores de trail
|
TR201809678T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
AU2002336446B2
(en)
|
2001-09-06 |
2008-03-06 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
WO2003047336A2
(en)
|
2001-11-30 |
2003-06-12 |
Abgenix, Inc. |
TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
EP1467756A4
(en)
|
2001-12-28 |
2007-03-21 |
Abgenix Inc |
METHODS OF USING ANTI-MUC18 ANTIBODIES
|
JP2005514409A
(ja)
|
2001-12-28 |
2005-05-19 |
アブジェニックス・インコーポレーテッド |
Muc18抗原に対する抗体の使用
|
US7135174B2
(en)
*
|
2002-01-07 |
2006-11-14 |
Amgen Fremont, Inc. |
Antibodies directed to PDGFD and uses thereof
|
NZ534174A
(en)
|
2002-01-09 |
2007-03-30 |
Medarex Inc |
An isolated human monoclonal antibody which binds to human CD30
|
DK2230299T3
(da)
|
2002-01-18 |
2012-03-26 |
Zymogenetics Inc |
Hidtil ukendt cytokin ZCYTOR17-ligand
|
ES2546797T3
(es)
|
2002-01-18 |
2015-09-28 |
Zymogenetics, Inc. |
Multímeros Zcytor17 receptores de citocinas
|
WO2003062278A1
(en)
|
2002-01-25 |
2003-07-31 |
G2 Therapies Ltd |
MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
|
AU2003218350A1
(en)
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
AU2003220525A1
(en)
|
2002-03-29 |
2003-10-20 |
Abgenix, Inc. |
Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
|
US7718776B2
(en)
*
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
US7541150B2
(en)
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
EP1499724B1
(en)
|
2002-04-18 |
2013-05-22 |
Yeda Research And Development Co., Ltd. |
Derivatives of the il-2 receptor gamma chain, their production and use
|
BR0309401A
(pt)
|
2002-04-19 |
2007-02-21 |
Zymogenetics Inc |
polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
|
ATE464389T1
(de)
|
2002-05-17 |
2010-04-15 |
Kyowa Hakko Kirin Co Ltd |
Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
|
JP2006508899A
(ja)
*
|
2002-05-20 |
2006-03-16 |
アブジエニツクス・インコーポレイテツド |
EGFrに対する抗体を使用する腎癌の治療方法
|
CA2488682C
(en)
|
2002-06-10 |
2014-04-01 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
JP2005535308A
(ja)
|
2002-06-13 |
2005-11-24 |
カイロン コーポレイション |
Hml−2ポリペプチド発現用ベクター
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US20040081653A1
(en)
|
2002-08-16 |
2004-04-29 |
Raitano Arthur B. |
Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
|
ES2384379T3
(es)
|
2002-09-06 |
2012-07-04 |
Amgen, Inc. |
Anticuerpo monoclonal anti-IL-1R1 humano terapéutico
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
EP1563084A4
(en)
|
2002-11-08 |
2006-03-01 |
Hematech Llc |
TRANSGENE UNGULATES WITH REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF
|
EP2287192B1
(en)
|
2002-11-15 |
2015-08-26 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
WO2004050683A2
(en)
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
CA2510315C
(en)
|
2002-12-20 |
2014-01-28 |
Protein Design Labs, Inc. |
Antibodies against gpr64 and uses thereof
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2515699C
(en)
|
2003-02-10 |
2015-01-27 |
Aya Jakobovits |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
WO2004073624A2
(en)
|
2003-02-14 |
2004-09-02 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
EP2058408A3
(en)
|
2003-02-14 |
2009-09-09 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
US8067544B2
(en)
|
2003-03-19 |
2011-11-29 |
Curagen Corporation |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
KR101106441B1
(ko)
|
2003-03-19 |
2012-01-18 |
바이오겐 아이덱 엠에이 인코포레이티드 |
노고 수용체 결합 단백질
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
EP1633785B1
(en)
|
2003-05-21 |
2012-11-28 |
Medarex, Inc. |
Human monoclonal antibodies against bacillusanthracis protective antigen
|
NZ578591A
(en)
|
2003-05-30 |
2011-01-28 |
Agensys Inc |
Prostate stem cell antigen (PSCA) variants and subsequences thereof, namely SEQ ID NO: 6554
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
KR20120098932A
(ko)
|
2003-06-27 |
2012-09-05 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
EP1644408A1
(en)
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
MXPA06000508A
(es)
|
2003-07-18 |
2006-04-05 |
Amgen Inc |
Agentes de union especifica al factor del crecimiento de los hepatocitos.
|
CN1838968A
(zh)
|
2003-08-08 |
2006-09-27 |
艾伯吉尼斯公司 |
针对甲状旁腺激素(pth)之抗体和其用途
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
US20050153392A1
(en)
*
|
2003-08-11 |
2005-07-14 |
Roland Buelow |
Transgenesis with humanized immunoglobulin loci
|
EP1656392A2
(en)
*
|
2003-08-12 |
2006-05-17 |
Dyax Corp. |
Tie1-binding ligands
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
CN104013957B
(zh)
|
2003-12-23 |
2016-06-29 |
泰勒公司 |
用新的抗il13单克隆抗体治疗癌症
|
EP2322637B1
(en)
*
|
2003-12-24 |
2016-05-18 |
Novo Nordisk A/S |
Transgenic mouse comprising a polynucleotide encoding human or humanized C5AR
|
CA2552750C
(en)
|
2004-01-07 |
2021-11-09 |
Chiron Corporation |
M-csf-specific monoclonal antibody and uses thereof
|
DE602005026779D1
(de)
|
2004-01-09 |
2011-04-21 |
Pfizer |
ANTIKÖRPER GEGEN MAdCAM
|
AU2005211725B2
(en)
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
US7691379B2
(en)
|
2004-04-12 |
2010-04-06 |
Medimmune, Llc |
Anti-IL-9 antibody formulations
|
WO2005104835A2
(en)
|
2004-04-22 |
2005-11-10 |
Kirin Beer Kabushiki Kaisha |
Transgenic animals and uses thereof
|
NZ551627A
(en)
|
2004-05-28 |
2010-02-26 |
Agensys Inc |
Antibodies and related molecules that bind to PSCA proteins
|
CA2610632C
(en)
|
2004-06-01 |
2022-10-04 |
Mount Sinai School Of Medicine Of New York University |
Genetically engineered swine influenza virus and uses thereof
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
US8486893B2
(en)
|
2004-06-24 |
2013-07-16 |
Biogen Idec Ma Inc. |
Treatment of conditions involving demyelination
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
ATE481645T1
(de)
|
2004-07-14 |
2010-10-15 |
Univ California |
Biomarker für den frühzeitigen nachweis von ovarialkarzinom
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
NZ552091A
(en)
|
2004-07-16 |
2009-09-25 |
Pfizer Prod Inc |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
SI1776383T1
(sl)
|
2004-07-22 |
2014-12-31 |
Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics |
Vezavne molekule
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
US7709611B2
(en)
|
2004-08-04 |
2010-05-04 |
Amgen Inc. |
Antibodies to Dkk-1
|
KR101094617B1
(ko)
|
2004-08-16 |
2011-12-15 |
사일런스 테라퓨틱스 아게 |
알티피801 억제제의 치료적 용도
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
US20060045877A1
(en)
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
EP1793850A4
(en)
|
2004-09-21 |
2010-06-30 |
Medimmune Inc |
ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
|
CA2582016A1
(en)
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating cd30 positive lymphomas
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
EP1811832A4
(en)
|
2004-10-22 |
2009-12-30 |
Revivicor Inc |
NATIVES WITH GENETICALLY MODIFIED IMMUNE SYSTEMS
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン,インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
CA2587903A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen Fremont Inc. |
Fully human monoclonal antibodies to il-13
|
CN101102792A
(zh)
|
2004-11-19 |
2008-01-09 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
SG157423A1
(en)
|
2004-12-02 |
2009-12-29 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
JP2008522971A
(ja)
*
|
2004-12-03 |
2008-07-03 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症の発症の遅延または予防
|
KR20070085439A
(ko)
|
2004-12-06 |
2007-08-27 |
기린 비루 가부시키가이샤 |
인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
|
AU2005319404B2
(en)
|
2004-12-20 |
2011-10-20 |
Amgen Fremont Inc. |
Binding proteins specific for human Matriptase
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
ES2395953T3
(es)
|
2005-01-26 |
2013-02-18 |
Amgen Fremont Inc. |
Anticuerpos frente a interleucina-1 beta
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
JP5265923B2
(ja)
|
2005-02-07 |
2013-08-14 |
ジーンニュース インコーポレーテッド |
軽度の変形性関節症のバイオマーカーおよびその使用
|
CA2597924C
(en)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
US20090124993A1
(en)
|
2005-02-17 |
2009-05-14 |
Burkly Linda C |
Treating neurological disorders
|
ES2498794T3
(es)
|
2005-02-18 |
2014-09-25 |
Medarex, L.L.C. |
Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
|
MX2007009889A
(es)
|
2005-02-23 |
2007-09-07 |
Genentech Inc |
Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
|
EP2251037B1
(en)
|
2005-03-02 |
2015-01-14 |
Biogen Idec MA Inc. |
KIM-1 antibodies for treatment of TH1/TH2-mediated conditions
|
JP2008531730A
(ja)
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
US20080248047A1
(en)
|
2005-03-08 |
2008-10-09 |
Tapan Das |
Platform Antibody Compositions
|
EP1863848A4
(en)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
CORRESPONDING ANTIBODIES AND MOLECULES THAT ATTACH PROTEINS 161P2F10B
|
EP1863519B1
(en)
|
2005-03-31 |
2013-09-25 |
The General Hospital Corporation |
Modulating hgf/hgfr activity for treating lymphodema
|
PT2645106T
(pt)
|
2005-04-04 |
2017-09-18 |
Biogen Ma Inc |
Método para avaliar uma resposta imune a um agente terapêutico
|
EP2062591A1
(en)
|
2005-04-07 |
2009-05-27 |
Novartis Vaccines and Diagnostics, Inc. |
CACNA1E in cancer diagnosis detection and treatment
|
EP1910557A2
(en)
|
2005-04-07 |
2008-04-16 |
Chiron Corporation |
Cancer-related genes
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
WO2006113643A2
(en)
*
|
2005-04-20 |
2006-10-26 |
Amgen Fremont Inc. |
High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
|
NL1031674C2
(nl)
|
2005-04-25 |
2007-04-26 |
Pfizer |
Antilichamen tegen myostatine.
|
EP2444419A1
(en)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin antibodies
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
AU2007254715B2
(en)
|
2005-05-06 |
2013-08-29 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
|
AU2006244014B2
(en)
|
2005-05-10 |
2011-03-17 |
Biogen Ma Inc. |
Treating and evaluating inflammatory disorders
|
WO2006128083A2
(en)
|
2005-05-25 |
2006-11-30 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
CA2609600C
(en)
|
2005-05-27 |
2016-11-08 |
Biogen Idec Ma Inc. |
Tweak binding antibodies
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
EP3501537A1
(en)
|
2005-06-30 |
2019-06-26 |
Janssen Biotech, Inc. |
Anti-il23 antibodies, compositions, methods and uses
|
SG10201508322SA
(en)
|
2005-07-08 |
2015-11-27 |
Biogen Ma Inc |
Sp35 antibodies and uses thereof
|
RS54984B1
(sr)
|
2005-07-18 |
2016-11-30 |
Amgen Inc |
Humana anti-b7rp1 neutrališuća antitela
|
US8652469B2
(en)
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
EP2573114B1
(en)
|
2005-08-10 |
2016-03-30 |
MacroGenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP2500358A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
MY169746A
(en)
|
2005-08-19 |
2019-05-14 |
Abbvie Inc |
Dual variable domain immunoglobulin and uses thereof
|
JP5161777B2
(ja)
|
2005-09-07 |
2013-03-13 |
アムジェン フレモント インク. |
アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体
|
EP1945240B1
(en)
|
2005-09-16 |
2016-12-28 |
Raptor Pharmaceutical Inc |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
JP5237817B2
(ja)
|
2005-10-21 |
2013-07-17 |
ジーンニュース インコーポレーティッド |
バイオマーカー産物レベルを疾患に相関させるための方法および装置
|
PE20070796A1
(es)
*
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
DK2500030T4
(da)
|
2005-11-04 |
2018-10-29 |
Genentech Inc |
Anvendelse af komplementvejshæmmere til behandling af øjensygdomme
|
AU2006311828B2
(en)
|
2005-11-04 |
2013-07-11 |
Biogen Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
US20100028358A1
(en)
|
2005-11-07 |
2010-02-04 |
Wolfram Ruf |
Compositions and Methods for Controlling Tissue Factor Signaling Specificity
|
EP1951906B1
(en)
|
2005-11-10 |
2010-12-22 |
Bristol-Myers Squibb Pharma Company |
Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
|
AU2006315580A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
|
PT1951759E
(pt)
*
|
2005-11-12 |
2010-04-01 |
Lilly Co Eli |
Anticorpos anti-egfr
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
EP1963369B1
(en)
|
2005-11-28 |
2013-05-15 |
Zymogenetics, Inc. |
Il-21 antagonists
|
KR20140087058A
(ko)
|
2005-11-30 |
2014-07-08 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
EP2289909B1
(en)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
|
JP2009518314A
(ja)
|
2005-12-02 |
2009-05-07 |
ジェネンテック・インコーポレーテッド |
Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
|
AU2006320479B2
(en)
|
2005-12-02 |
2012-11-08 |
Biogen Ma Inc. |
Treatment of conditions involving demyelination
|
CA2631812C
(en)
|
2005-12-02 |
2023-08-29 |
Peter Palese |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
US20070134249A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Genitope Corporation |
Combination therapy and antibody panels
|
JP5302007B2
(ja)
|
2005-12-13 |
2013-10-02 |
アストラゼネカ アクチボラグ |
インスリン様増殖因子に特異的な結合タンパク質およびその使用
|
US7763245B2
(en)
|
2005-12-15 |
2010-07-27 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
ES2411505T3
(es)
|
2005-12-15 |
2013-07-05 |
Medimmune Limited |
Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer
|
US7745587B2
(en)
|
2005-12-30 |
2010-06-29 |
Dyax Corp. |
Antibodies that bind MMP-14
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
NZ599035A
(en)
|
2006-01-12 |
2013-12-20 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
KR101611322B1
(ko)
|
2006-01-18 |
2016-04-11 |
더 제너럴 하스피탈 코포레이션 |
림프 기능을 증가시키는 방법
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
CA2638117A1
(en)
|
2006-01-25 |
2007-08-30 |
Erasmus University Medical Center Rotterdam |
Generation of heavy-chain only antibodies in transgenic animals
|
PT1981902E
(pt)
|
2006-01-27 |
2015-11-02 |
Biogen Ma Inc |
Antagonistas dos recetores nogo
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
WO2007111661A2
(en)
|
2006-03-20 |
2007-10-04 |
Xoma Technology Ltd. |
Human antibodies specific for gastrin materials and methods
|
US8252547B2
(en)
|
2006-03-20 |
2012-08-28 |
Japan Science And Technology Agency |
In vitro control of protein synthesis in mammalian cells by IP3 receptor-binding protein
|
WO2007117410A2
(en)
|
2006-03-31 |
2007-10-18 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
AU2007234733A1
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
MX2008013121A
(es)
|
2006-04-13 |
2009-03-25 |
Novartis Vaccines & Diagnostic |
Metodo para tratar, diagnosticar o detectar cancer.
|
JP5496658B2
(ja)
|
2006-05-25 |
2014-05-21 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脳卒中を処置する方法
|
ES2567402T3
(es)
|
2006-05-30 |
2016-04-22 |
Genentech, Inc. |
Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
|
AR061170A1
(es)
|
2006-06-02 |
2008-08-06 |
Aveo Pharmaceuticals Inc |
Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
|
PT2027156E
(pt)
|
2006-06-02 |
2011-04-18 |
Aveo Pharmaceuticals Inc |
Proteínas de ligação ao factor de crescimento de hepatócito (hgf)
|
MX2008015541A
(es)
|
2006-06-06 |
2008-12-18 |
Genentech Inc |
Anticuerpos anti-dll4 y metodos que los usan.
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
ES2381731T3
(es)
|
2006-06-28 |
2012-05-31 |
Yeda Research And Development Co. Ltd. |
Caspasa-8 y cicatrización de heridas
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5605895B2
(ja)
|
2006-07-04 |
2014-10-15 |
ゲンマブ エー/エス |
Copdを処置するためのcd20結合分子
|
EP2479284B1
(en)
|
2006-07-13 |
2017-09-20 |
University of Iowa Research Foundation |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
JP5362563B2
(ja)
|
2006-08-03 |
2013-12-11 |
アストラゼネカ・アクチエボラーグ |
αVβ6に対する抗体およびその使用
|
EP2054444B1
(en)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antibodies to erbb2
|
ES2452067T3
(es)
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
PE20081214A1
(es)
|
2006-08-18 |
2008-09-24 |
Novartis Ag |
Anticuerpo especifico prlr y sus usos
|
EP2051997B1
(en)
|
2006-08-22 |
2015-03-18 |
G2 Inflammation Pty Ltd |
Anti-c5ar antibodies with improved properties
|
PT2292663E
(pt)
|
2006-08-28 |
2013-11-04 |
Kyowa Hakko Kirin Co Ltd |
Anticorpos monoclonais humanos antagonistas específicos de light humano
|
PL2059533T3
(pl)
|
2006-08-30 |
2013-04-30 |
Genentech Inc |
Przeciwciała wieloswoiste
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
CN101506235B
(zh)
|
2006-09-01 |
2012-07-25 |
人类多细胞株治疗学公司 |
人或人源化免疫球蛋白在非人转基因动物中增强的表达
|
NZ599144A
(en)
|
2006-09-08 |
2013-10-25 |
Abbott Lab |
Interleukin -13 binding proteins
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
US9492518B2
(en)
|
2006-10-04 |
2016-11-15 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
AU2007308145A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
RS53942B1
(en)
|
2006-10-27 |
2015-08-31 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
EP2395077A1
(en)
|
2006-11-03 |
2011-12-14 |
Wyeth LLC |
Glycolysis-inhibiting substances in cell culture
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
JP2010510772A
(ja)
|
2006-11-27 |
2010-04-08 |
パトリス リミテッド |
新生細胞における新規なグリコシル化ペプチド標的
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
KR20140119831A
(ko)
|
2006-12-07 |
2014-10-10 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
ZA200904022B
(en)
|
2006-12-08 |
2010-08-25 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against ANGPTL3
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
EP3124045A3
(en)
|
2006-12-20 |
2017-05-03 |
Xoma (Us) Llc |
Treatment of il-1 beta related diseases
|
ES2635317T3
(es)
|
2007-01-05 |
2017-10-03 |
University Of Zurich |
Anticuerpo anti-beta-amiloide y sus usos
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
JP2010515456A
(ja)
|
2007-01-09 |
2010-05-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Sp35抗体およびその使用
|
KR20090100461A
(ko)
|
2007-01-16 |
2009-09-23 |
아보트 러보러터리즈 |
건선의 치료방법
|
MX2009008430A
(es)
|
2007-02-09 |
2009-10-28 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos.
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
WO2008101352A1
(en)
*
|
2007-02-22 |
2008-08-28 |
Simonson Roger M |
Magnetic filter and magnetic filtering assembly
|
DK2140021T3
(da)
|
2007-02-22 |
2012-05-07 |
Genentech Inc |
Fremgangsmåder til detektion af inflammatorisk tarmsygdom.
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
US20090075267A1
(en)
|
2007-03-13 |
2009-03-19 |
Salvatore Siena |
K-ras and B-raf mutations and anti-EGFr antibody therapy
|
CA2680326A1
(en)
|
2007-03-13 |
2008-09-18 |
Amgen Inc. |
K-ras mutations and anti-egfr antibody therapy
|
EP2474556A3
(en)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1 inhibitors for treating, diagnosing or detecting cancer
|
TWI417299B
(zh)
|
2007-03-22 |
2013-12-01 |
Biogen Idec Inc |
包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
NZ580379A
(en)
|
2007-03-29 |
2012-10-26 |
Abbott Lab |
Crystalline anti-human il-12 antibodies
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
CA2682927A1
(en)
|
2007-04-02 |
2008-10-16 |
Amgen Fremont Inc. |
Anti-ige antibodies
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
PT3072525T
(pt)
|
2007-05-14 |
2018-04-20 |
Astrazeneca Ab |
Métodos para reduzir os níveis de basófilos
|
ES2661249T3
(es)
|
2007-05-21 |
2018-03-28 |
Genentech, Inc. |
Métodos y composiciones para identificar y tratar el lupus
|
PL2152880T3
(pl)
|
2007-06-01 |
2012-03-30 |
Omt Inc |
Kompozycje i sposoby hamowania endogennych genów immunoglobuliny i wytwarzania transgenicznych ludzkich idiotypowych przeciwciał
|
DK2171090T3
(da)
|
2007-06-08 |
2013-06-10 |
Genentech Inc |
Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
|
CA2690382A1
(en)
|
2007-06-14 |
2008-12-24 |
Biogen Idec Ma Inc. |
Antibody formulations
|
KR101799337B1
(ko)
|
2007-06-21 |
2017-12-20 |
마크로제닉스, 인크. |
공유결합형 디아바디 및 이것의 사용
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
US20090053786A1
(en)
|
2007-07-09 |
2009-02-26 |
Yung-Hsiang Kao |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
CA2695237A1
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
BRPI0815368A2
(pt)
|
2007-08-21 |
2015-02-10 |
Amgen Inc |
"proteinas c-fms humanas a antigeno"
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
WO2009032661A1
(en)
|
2007-08-29 |
2009-03-12 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
EP2193142B1
(en)
|
2007-08-30 |
2015-01-07 |
CureDM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
EP2198304B1
(en)
|
2007-09-06 |
2016-01-13 |
University of Washington |
Molecules and methods for treatment and detection of diabetes
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
WO2009040134A1
(en)
|
2007-09-26 |
2009-04-02 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
US8383114B2
(en)
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
KR20100098620A
(ko)
|
2007-11-05 |
2010-09-08 |
메디뮨 엘엘씨 |
경피증의 치료 방법
|
KR101620642B1
(ko)
|
2007-11-07 |
2016-05-12 |
제넨테크, 인크. |
항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물
|
KR101867606B1
(ko)
|
2007-11-07 |
2018-06-18 |
제넨테크, 인크. |
미생물 질환의 치료를 위한 조성물 및 방법
|
SG10201405835TA
(en)
|
2007-11-12 |
2014-10-30 |
U3 Pharma Gmbh |
Axl antibodies
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
US8715941B2
(en)
|
2007-11-16 |
2014-05-06 |
Arca Biopharma, Inc. |
Antibodies to LRP6
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
JP5536666B2
(ja)
|
2007-12-20 |
2014-07-02 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
痛風の治療のための方法
|
AU2008343855B2
(en)
|
2007-12-21 |
2013-08-15 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
JP2011508738A
(ja)
|
2007-12-26 |
2011-03-17 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138発現腫瘍細胞のターゲティングを向上させる方法及び剤
|
RU2537265C2
(ru)
|
2007-12-26 |
2014-12-27 |
Биотест Аг |
Агенты против клетки-мишени, нацеленные на cd138, и их применение
|
HUE024291T2
(en)
|
2007-12-26 |
2016-01-28 |
Biotest Ag |
Immunoconjugates and Applications for CD138
|
AR069979A1
(es)
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
|
EP2244729B1
(en)
|
2008-01-18 |
2016-11-02 |
MedImmune, LLC |
Cysteine engineered antibodies for site-specific conjugation
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
KR101666229B1
(ko)
|
2008-02-08 |
2016-10-14 |
메디뮨 엘엘씨 |
Fc 리간드 친화성이 감소된 항-IFNAR1 항체
|
IL189408A0
(en)
|
2008-02-10 |
2009-02-11 |
Yeda Res & Dev |
Siva3, its preparation and pharmaceutical compositions containing it
|
EP2826791A3
(en)
|
2008-02-20 |
2015-07-29 |
Novo Nordisk A/S |
Humanized anti-C5aR antibodies
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
EP2274333A4
(en)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
PROCESS FOR TREATING PSORIASIS
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
RU2607569C2
(ru)
|
2008-03-31 |
2017-01-10 |
Дженентек, Инк. |
Композиции и способы для лечения и диагностики астмы
|
WO2009129247A2
(en)
|
2008-04-14 |
2009-10-22 |
Innovative Targeting Solutions Inc. |
Sequence diversity generation in immunoglobulins
|
CA2722082C
(en)
|
2008-04-25 |
2021-11-09 |
Christopher Tenhoor |
Fc receptor binding proteins
|
JP5593220B2
(ja)
|
2008-04-25 |
2014-09-17 |
東レ株式会社 |
C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
EP2294087B1
(en)
|
2008-05-01 |
2014-05-14 |
Amgen, Inc. |
Anti-hepcidin antibodies and methods of use
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
AR071698A1
(es)
|
2008-05-09 |
2010-07-07 |
Abbott Gmbh & Co Kg |
Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
|
EP2304439A4
(en)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
ANTI-phospho-AKT ANTIBODY
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
AU2009256246B2
(en)
|
2008-06-03 |
2013-07-18 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
ES2595362T3
(es)
|
2008-06-16 |
2016-12-29 |
Patrys Limited |
Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
KR20110040886A
(ko)
|
2008-07-08 |
2011-04-20 |
아보트 러보러터리즈 |
프로스타글란딘 e2 결합 단백질 및 이의 용도
|
EP2321422A4
(en)
|
2008-07-08 |
2013-06-19 |
Abbvie Inc |
PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
AR073060A1
(es)
|
2008-08-14 |
2010-10-13 |
Arana Therapeutic Ltd |
Anticuerpos anti-il-12/il-23
|
CN102239180B
(zh)
|
2008-08-18 |
2014-12-31 |
辉瑞大药厂 |
抗ccr2抗体
|
US8193321B2
(en)
|
2008-09-03 |
2012-06-05 |
Genentech, Inc. |
Multispecific antibodies
|
ES2549877T3
(es)
|
2008-09-07 |
2015-11-02 |
Glyconex Inc. |
Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización
|
KR20110057244A
(ko)
|
2008-09-19 |
2011-05-31 |
메디뮨 엘엘씨 |
Dll4에 대한 항체 및 이의 용도
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
WO2010039900A2
(en)
|
2008-09-30 |
2010-04-08 |
Aliva Biopharmaceuticals, Inc. |
Non-human mammals for the production of chimeric antibodies
|
SG10201605250SA
(en)
|
2008-10-14 |
2016-08-30 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
JP2012505900A
(ja)
|
2008-10-14 |
2012-03-08 |
ダイアクス コーポレーション |
全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用
|
CA2741523C
(en)
|
2008-10-24 |
2022-06-21 |
Jonathan S. Towner |
Human ebola virus species and compositions and methods thereof
|
WO2010051288A1
(en)
|
2008-10-27 |
2010-05-06 |
Revivicor, Inc. |
Immunocompromised ungulates
|
AR073997A1
(es)
|
2008-10-29 |
2010-12-15 |
Wyeth Corp |
Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
|
KR20110079693A
(ko)
|
2008-10-29 |
2011-07-07 |
와이어쓰 엘엘씨 |
단일 도메인 항원 결합 분자의 정제 방법
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP3101031A1
(en)
|
2008-11-10 |
2016-12-07 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
US20140086919A1
(en)
*
|
2012-09-24 |
2014-03-27 |
Herbert Y. Lin |
Methods and compositons for regulating iron homeostasis by modulation of bmp-6
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
US20100172862A1
(en)
*
|
2008-11-28 |
2010-07-08 |
Abbott Laboratories |
Stable antibody compositions and methods of stabilizing same
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
PL2376535T3
(pl)
|
2008-12-09 |
2017-09-29 |
F.Hoffmann-La Roche Ag |
Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
|
US20110314563A1
(en)
*
|
2008-12-18 |
2011-12-22 |
Kingdon Craig R |
Antibody production
|
BRPI0918122A8
(pt)
|
2008-12-19 |
2017-01-24 |
Macrogenics Inc |
molécula de diabody, diabody, e mólecula dart
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
AU2009329866B2
(en)
|
2008-12-23 |
2016-09-29 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein A
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2379595A2
(en)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Targeted binding agents directed to 5 1 and uses thereof
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
EP2389195B1
(en)
|
2009-01-20 |
2015-05-20 |
Homayoun H. Zadeh |
Antibody mediated osseous regeneration
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US8309530B2
(en)
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
EP2394159B1
(en)
|
2009-02-04 |
2018-09-26 |
Molecular Innovations |
Assays for detecting prorenin, and antibodies used therein
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
EP2772269A3
(en)
|
2009-03-05 |
2015-01-14 |
Abbvie Inc. |
IL-17 binding proteins
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
CA2755336C
(en)
|
2009-03-20 |
2015-07-14 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
EP2411412B1
(en)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanized antibodies against light and uses thereof
|
US9051359B2
(en)
|
2009-03-30 |
2015-06-09 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
BRPI1011535A2
(pt)
|
2009-04-01 |
2016-03-29 |
Genentech Inc |
tratamento de distúrbios resistentes à insulina.
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
BRPI1012524A2
(pt)
|
2009-04-16 |
2020-09-29 |
Abbott Biotherapeutics Corp |
anticorpos anti-tnf-alfa e seus usos
|
JP2013525260A
(ja)
*
|
2009-04-17 |
2013-06-20 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
急性骨髄性白血病を治療するための組成物および方法
|
CN102459639A
(zh)
|
2009-04-18 |
2012-05-16 |
健泰科生物技术公司 |
用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
|
HUE025966T2
(en)
|
2009-04-27 |
2016-05-30 |
Kyowa Hakko Kirin Co Ltd |
Anti-IL-3RA antibody for use in the treatment of blood cancer
|
JP5925116B2
(ja)
|
2009-04-29 |
2016-05-25 |
ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド |
Ergモノクローナル抗体
|
RU2605318C2
(ru)
|
2009-05-05 |
2016-12-20 |
Новиммун С.А. |
Анти-il-17f антитела и способы их применения
|
JP5941841B2
(ja)
|
2009-05-26 |
2016-06-29 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
RU2567639C2
(ru)
|
2009-06-17 |
2015-11-10 |
АббВай Биотерапеутикс Инк., |
Антитела против vegf и их применения
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
EP2604110B1
(en)
|
2009-07-08 |
2016-11-30 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
EP2451487A1
(en)
|
2009-07-09 |
2012-05-16 |
F. Hoffmann-La Roche AG |
In vivi tumor vasculature imaging
|
CA2766403A1
(en)
|
2009-07-13 |
2011-01-20 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011014504A1
(en)
|
2009-07-27 |
2011-02-03 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza virus vectors and uses thereof
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
US8828406B2
(en)
|
2009-07-30 |
2014-09-09 |
Icahn School Of Medicine At Mount Sinai |
Influenza viruses and uses thereof
|
CN102498129B
(zh)
|
2009-07-31 |
2016-03-02 |
霍夫曼-拉罗奇有限公司 |
使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
US8512983B2
(en)
|
2009-08-11 |
2013-08-20 |
Martin Gawlitzek |
Production of proteins in glutamine-free cell culture media
|
EP2464220A4
(en)
|
2009-08-13 |
2014-05-07 |
Crystal Bioscience Inc |
Transgenic animal for the production of antibodies with minimal complementarity-determining regions
|
US8568719B2
(en)
|
2009-08-13 |
2013-10-29 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (RSV) and methods of use
|
CN102575298A
(zh)
|
2009-08-14 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
用于监测患者对vegf拮抗剂的响应的生物学标志物
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
JP5903382B2
(ja)
|
2009-08-29 |
2016-04-13 |
アッヴィ・インコーポレイテッド |
治療用dll4結合タンパク質
|
EP2473524A4
(en)
|
2009-09-01 |
2013-05-22 |
Abbott Lab |
IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3211094A3
(en)
|
2009-09-03 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
JO3246B1
(ar)
|
2009-09-09 |
2018-03-08 |
Regeneron Pharma |
اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
|
EP2475996A1
(en)
|
2009-09-11 |
2012-07-18 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
TW201127400A
(en)
|
2009-09-14 |
2011-08-16 |
Abbott Lab |
Methods for treating psoriasis
|
AU2010297344A1
(en)
|
2009-09-17 |
2012-02-23 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2480888B1
(en)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening methods
|
KR101108642B1
(ko)
|
2009-09-29 |
2012-02-09 |
주식회사 녹십자 |
표피 성장 인자 수용체에 특이적으로 결합하는 항체
|
KR101782180B1
(ko)
|
2009-09-30 |
2017-10-23 |
제넨테크, 인크. |
Notch3 길항제를 사용한 Notch1―길항제-내성 암(들)의 치료
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
WO2011044205A1
(en)
|
2009-10-07 |
2011-04-14 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring lupus
|
BR112012007760A2
(pt)
|
2009-10-07 |
2015-08-25 |
Macrogenics Inc |
Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
|
WO2011044553A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
PE20121531A1
(es)
|
2009-10-15 |
2012-12-22 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
RU2642295C2
(ru)
|
2009-10-26 |
2018-01-24 |
Дженентек, Инк. |
АНАЛИЗЫ ОПРЕДЕЛЕНИЯ АНТИТЕЛ, СПЕЦИФИЧНЫХ К ТЕРАПЕВТИЧЕСКИМ АНТИТЕЛАМ ПРОТИВ IgE, И ИХ ПРИМЕНЕНИЕ ПРИ АНАФИЛАКСИИ
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN102753580A
(zh)
|
2009-10-28 |
2012-10-24 |
亚培生物医疗股份有限公司 |
抗egfr抗体及其用途
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120277144A1
(en)
|
2009-11-04 |
2012-11-01 |
Henricus Johannes Duckers |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
ES2655737T3
(es)
|
2009-11-13 |
2018-02-21 |
Daiichi Sankyo Europe Gmbh |
Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
US20120231006A1
(en)
*
|
2009-11-20 |
2012-09-13 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
TW201636048A
(zh)
|
2009-12-21 |
2016-10-16 |
建南德克公司 |
抗體調配物
|
HUE038684T2
(hu)
|
2009-12-21 |
2018-11-28 |
Regeneron Pharma |
Humanizált FC gamma R génnel rendelkezõ egér
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック, インコーポレイテッド |
抗Bv8抗体およびその使用
|
SI2521568T1
(sl)
|
2010-01-06 |
2019-01-31 |
Dyax Corp. |
Proteini, ki vežejo plazemski kalikrein
|
SG182408A1
(en)
|
2010-01-11 |
2012-08-30 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
WO2011088120A1
(en)
|
2010-01-15 |
2011-07-21 |
Amgen Inc. |
Antibody formulation and therapeutic regimens
|
US8865462B2
(en)
|
2010-01-20 |
2014-10-21 |
Crystal Bioscience Inc. |
Sustained culture of avian gonocytes
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
ME02288B
(me)
|
2010-02-08 |
2016-02-20 |
Regeneron Pharma |
Miš sa zajedničkim lakim lancem
|
AU2011215900A1
(en)
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
US9029509B2
(en)
|
2010-02-12 |
2015-05-12 |
The Regents Of The University Of California |
Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)
|
JP2013520172A
(ja)
|
2010-02-18 |
2013-06-06 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
|
PE20130580A1
(es)
|
2010-03-02 |
2013-06-02 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
JP2013526849A
(ja)
|
2010-03-30 |
2013-06-27 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルスワクチン及びその使用
|
NZ601171A
(en)
|
2010-03-31 |
2014-11-28 |
Ablexis Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
JP2013523184A
(ja)
|
2010-04-15 |
2013-06-17 |
アムジエン・インコーポレーテツド |
ヒトFGF受容体およびβ−KLOTHO結合性タンパク質
|
EP2558494B1
(en)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
EP4032912A1
(en)
|
2010-04-16 |
2022-07-27 |
Biogen MA Inc. |
Anti-vla-4 antibodies
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
PL2563813T3
(pl)
|
2010-04-30 |
2016-01-29 |
Alexion Pharma Inc |
Przeciwciała anty-C5a i sposoby stosowania przeciwciał
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
US9403855B2
(en)
|
2010-05-10 |
2016-08-02 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
HUE033063T2
(hu)
|
2010-05-14 |
2017-11-28 |
Abbvie Inc |
IL-1 kötõ fehérjék
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
KR101834026B1
(ko)
|
2010-06-19 |
2018-03-02 |
메모리얼 슬로안-케터링 캔서 센터 |
항-gd2 항체
|
RS55037B1
(sr)
*
|
2010-06-22 |
2016-12-30 |
Regeneron Pharma |
Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
|
BR112012033119A2
(pt)
|
2010-06-22 |
2016-10-25 |
Univ Colorado Regents |
anticorpos para o fragamento c3d do componente do complemento 3.
|
US20130143797A1
(en)
|
2010-06-25 |
2013-06-06 |
Michael J. Tisdale |
Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof
|
WO2012012141A1
(en)
|
2010-06-30 |
2012-01-26 |
Amgen Inc. |
Scnn1a/tnfrsf1a fusion proteins in cancer
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
AU2011274472B2
(en)
|
2010-07-09 |
2017-03-30 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
MX2013000676A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
|
EP2848940A1
(en)
|
2010-07-19 |
2015-03-18 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
GB201012420D0
(en)
|
2010-07-23 |
2010-09-08 |
Univ Erasmus Medical Ct |
Foetal heamoglobin inhibitor
|
GB201012410D0
(en)
|
2010-07-23 |
2010-09-08 |
Medical Res Council |
Intracellular immunity
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
CN103025884B
(zh)
|
2010-07-26 |
2015-11-25 |
特里安尼公司 |
转基因动物和使用方法
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
DK2598526T3
(da)
|
2010-07-29 |
2018-11-19 |
Eleven Biotherapeutics Inc |
Kimæriske il-1-receptortype-i-agonister og -antagonister
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
SI2601298T1
(sl)
|
2010-08-02 |
2017-03-31 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki ustvarjajo proteine za vezavo, obsegajoče vl domene
|
NZ607480A
(en)
|
2010-08-03 |
2014-10-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
JP2013540694A
(ja)
|
2010-08-06 |
2013-11-07 |
ウー3・フアルマ・ゲー・エム・ベー・ハー |
Her3結合剤の前立腺治療における使用
|
MX2013001632A
(es)
|
2010-08-10 |
2013-06-05 |
Amgen Inc |
Ensayo de enlace objetivo in vitro de funcion doble para la deteccion de anticuerpos neutralizantes contra anticuerpos objetivo.
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
ES2665954T3
(es)
|
2010-08-19 |
2018-04-30 |
Zoetis Belgium S.A. |
Anticuerpos anti-NGF y su uso
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
MX360946B
(es)
|
2010-09-22 |
2018-10-29 |
Amgen Inc Star |
Inmunoglobulinas portadoras y usos de las mismas.
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
WO2012058393A2
(en)
|
2010-10-27 |
2012-05-03 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
EP2640738A1
(en)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
JP6033229B2
(ja)
|
2010-11-24 |
2016-11-30 |
レクシコン ファーマシューティカルズ インコーポレイテッド |
Notumペクチンアセチルエステラーゼと結合する抗体
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
US8853365B2
(en)
|
2010-12-21 |
2014-10-07 |
Abbvie Inc. |
Dual variable domain immunnoglobulins and uses thereof
|
JP6147670B2
(ja)
|
2010-12-22 |
2017-06-14 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
改善された半減期を有する修飾された抗体
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
WO2012099983A1
(en)
|
2011-01-18 |
2012-07-26 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
CA2824885A1
(en)
|
2011-01-19 |
2012-07-26 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
EP3744850A1
(en)
|
2011-02-25 |
2020-12-02 |
Regeneron Pharmaceuticals, Inc. |
Adam6 mice
|
CA2827859A1
(en)
|
2011-02-28 |
2012-09-07 |
Genentech, Inc. |
Biological markers and methods for predicting response to b-cell antagonists
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
PL3235508T3
(pl)
|
2011-03-16 |
2021-07-12 |
Sanofi |
Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
|
US20140010756A1
(en)
|
2011-03-18 |
2014-01-09 |
Kagoshima University |
Composition for treatment and diagnosis of pancreatic cancer
|
CN103547592A
(zh)
|
2011-03-30 |
2014-01-29 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
EP2952210A3
(en)
|
2011-04-07 |
2016-03-16 |
Emory University |
Compositions comprising saccharide binding moieties and methods for targeted therapy
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
EP3623381A1
(en)
|
2011-05-19 |
2020-03-18 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
US9376495B2
(en)
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
WO2012167173A1
(en)
|
2011-06-02 |
2012-12-06 |
The University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
CN105622754B
(zh)
|
2011-06-02 |
2019-12-27 |
戴埃克斯有限公司 |
Fc受体结合蛋白
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
EP3798230B1
(en)
|
2011-06-06 |
2022-08-03 |
Novo Nordisk A/S |
Therapeutic antibodies
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
EP2718327A1
(en)
|
2011-06-06 |
2014-04-16 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
CA2838211C
(en)
|
2011-06-10 |
2023-08-01 |
Medimmmune Limited |
Anti-pseudomonas psl binding molecules and uses thereof
|
JP2014520123A
(ja)
|
2011-06-17 |
2014-08-21 |
アムジエン・インコーポレーテツド |
Clec−2を使用して代謝性障害を治療または改善させる方法
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
MX2014000531A
(es)
|
2011-07-13 |
2014-12-05 |
Abbvie Inc |
Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
CA2844070A1
(en)
|
2011-08-05 |
2013-02-14 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
CN103890008A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
在顽固性肿瘤中抑制血管发生
|
JP2014528066A
(ja)
|
2011-09-09 |
2014-10-23 |
アムジエン・インコーポレーテツド |
癌治療での、EGFrに結合する薬剤を確立することにおける、ヒトパピローマウイルスステータスの使用
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
EP3839049A3
(en)
|
2011-09-19 |
2021-10-20 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
CA2849434A1
(en)
|
2011-09-20 |
2013-03-28 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
IN2014CN02113A
(da)
|
2011-09-21 |
2015-05-29 |
Fujirebio Kk |
|
CN104136461B
(zh)
|
2011-09-22 |
2021-06-08 |
安姆根有限公司 |
Cd27l抗原结合蛋白
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
NZ721184A
(en)
|
2011-09-30 |
2018-08-31 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
CA2849011A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
CN108200885B
(zh)
|
2011-10-17 |
2021-12-14 |
瑞泽恩制药公司 |
受限制的免疫球蛋白重链基因座
|
IN2014CN03936A
(da)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
WO2013063361A1
(en)
|
2011-10-28 |
2013-05-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified t cell receptor mice
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
RS56656B1
(sr)
|
2011-10-28 |
2018-03-30 |
Regeneron Pharma |
Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
|
PT3590332T
(pt)
|
2011-10-28 |
2022-05-27 |
Regeneron Pharma |
Ratinhos geneticamente modificados que expressam moléculas quiméricas de complexo principal de histocompatibilidade (mhc) ii
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
ES2936387T3
(es)
|
2011-10-31 |
2023-03-16 |
Hoffmann La Roche |
Formulaciones de anticuerpos anti-il13
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
WO2013068432A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
BR112014011912A2
(pt)
|
2011-11-16 |
2017-05-16 |
Amgen Inc |
método para o tratamento de um mamífero que tem um tumor
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
KR20140100571A
(ko)
|
2011-12-08 |
2014-08-14 |
바이오테스트 아게 |
Cd138을 타겟팅하는 면역접합체의 용도
|
AU2012347540A1
(en)
|
2011-12-08 |
2014-06-26 |
Amgen Inc. |
Agonistic human LCAT antigen binding proteins and their use in therapy
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CA3204283A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2794657B1
(en)
|
2011-12-19 |
2017-10-11 |
Xoma (Us) Llc |
Methods for treating acne
|
PT2793567T
(pt)
|
2011-12-20 |
2019-05-27 |
Regeneron Pharma |
Murganhos de cadeia leve humanizada
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
AU2013207778B2
(en)
|
2012-01-13 |
2017-10-12 |
Genentech, Inc. |
Biological markers for identifying patients for treatment with VEGF antagonists
|
WO2013107290A1
(en)
|
2012-01-20 |
2013-07-25 |
The Government of the Hong Kong Special Administrative Region of the People's Republic of China |
A novel paramyxovirus and uses thereof
|
RU2017145268A
(ru)
|
2012-01-27 |
2019-02-18 |
Эббви Дойчланд Гмбх Унд Ко. Кг |
Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
|
CA2863066A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
PT2812443T
(pt)
|
2012-02-06 |
2019-09-05 |
Inhibrx Inc |
Anticorpos cd47 e métodos de utilização dos mesmos
|
GB201202268D0
(en)
|
2012-02-09 |
2012-03-28 |
Medical Res Council |
Intracellular immunity
|
CN108324943B
(zh)
|
2012-02-10 |
2024-03-08 |
思进股份有限公司 |
Cd30+癌症的检测和治疗
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
SI2814844T1
(sl)
|
2012-02-15 |
2017-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo in blokirajo sprožilni receptor, izražen na mieloidnih celicah-1 (trem-1)
|
WO2013120554A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
EP2814468B1
(en)
|
2012-02-16 |
2019-06-19 |
Santarus, Inc. |
Anti-vla1 (cd49a) antibody pharmaceutical compositions
|
CA2864702A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
NZ628458A
(en)
|
2012-03-27 |
2016-11-25 |
Genentech Inc |
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
WO2013148288A1
(en)
|
2012-03-30 |
2013-10-03 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
CN110078818B
(zh)
|
2012-04-27 |
2023-12-29 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
WO2013165590A1
(en)
|
2012-05-03 |
2013-11-07 |
Fibrogen, Inc. |
Methods for treating idiopathic pulmonary fibrosis
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
US9441039B2
(en)
|
2012-05-07 |
2016-09-13 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
MX2014013950A
(es)
|
2012-05-14 |
2015-02-17 |
Biogen Idec Inc |
Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
|
US9512223B2
(en)
|
2012-05-15 |
2016-12-06 |
Morphotek, Inc. |
Methods for treatment of gastric cancer
|
CA3062003C
(en)
|
2012-05-17 |
2022-01-11 |
Extend Biosciences, Inc. |
Vitamin d as a targeting group for therapeutic peptides
|
CN104918956A
(zh)
|
2012-05-17 |
2015-09-16 |
索伦托治疗有限公司 |
与egfr结合的抗原结合蛋白
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
AU2013267267B2
(en)
|
2012-05-31 |
2017-10-26 |
Genentech, Inc. |
Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
|
EP2859018B1
(en)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Caninized anti-ngf antibodies and methods thereof
|
NZ717848A
(en)
*
|
2012-06-12 |
2019-03-29 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
RU2015101803A
(ru)
|
2012-06-22 |
2016-08-20 |
Сайтомкс Терапьютикс, Инк. |
Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
|
JP6103832B2
(ja)
|
2012-06-25 |
2017-03-29 |
Hoya株式会社 |
Egfr結合性ペプチド
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
AU2013289971A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of CAR T cells by co-introducing a bispecific antibody
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
EP2885311B1
(en)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
KR20200079565A
(ko)
|
2012-08-31 |
2020-07-03 |
이뮤노젠 아이엔씨 |
엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
TW201922795A
(zh)
|
2012-09-10 |
2019-06-16 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
EP2904106A4
(en)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
|
NO2760138T3
(da)
|
2012-10-01 |
2018-08-04 |
|
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
AR093311A1
(es)
|
2012-11-01 |
2015-05-27 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
EP3686218A1
(en)
|
2012-12-10 |
2020-07-29 |
Biogen MA Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
FI3653049T3
(fi)
*
|
2012-12-14 |
2023-11-02 |
Omniab Inc |
Polynukleotidit, jotka koodaavat jyrsijän vasta-aineita, joissa on ihmisen idiotyyppejä, ja näitä käsittävät eläimet
|
JP2016508133A
(ja)
|
2012-12-18 |
2016-03-17 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルスワクチン及びその使用
|
US9574000B2
(en)
|
2012-12-19 |
2017-02-21 |
Medimmune, Llc |
Anti-human B7-H4 antibodies and their uses
|
BR112015014621A2
(pt)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
JP2016507555A
(ja)
|
2013-02-06 |
2016-03-10 |
インヒブルクス エルピー |
血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
LT2958938T
(lt)
|
2013-02-20 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
|
KR20160025033A
(ko)
|
2013-02-20 |
2016-03-07 |
리제너론 파마슈티칼스 인코포레이티드 |
변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
|
EP2958937B1
(en)
|
2013-02-22 |
2018-08-15 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
AR094873A1
(es)
|
2013-02-25 |
2015-09-02 |
Genentech Inc |
Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos
|
ES2858472T3
(es)
|
2013-03-11 |
2021-09-30 |
Amgen Inc |
Formulaciones proteínicas
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
PL2968555T3
(pl)
|
2013-03-13 |
2020-11-16 |
Sanofi |
Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
CN105392494A
(zh)
|
2013-03-13 |
2016-03-09 |
十一生物治疗股份有限公司 |
用于眼部递送的嵌合细胞因子制剂
|
KR102237885B1
(ko)
|
2013-03-13 |
2021-04-07 |
제넨테크, 인크. |
감소된 산화를 갖는 제제
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
EP2967012B1
(en)
|
2013-03-14 |
2020-09-16 |
Erasmus University Medical Center Rotterdam |
Transgenic non-human mammal for antibody production
|
MX2015012922A
(es)
|
2013-03-14 |
2016-04-04 |
Ren Liu |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
ES2672989T3
(es)
|
2013-03-15 |
2018-06-19 |
Sutter Bay Hospitals |
FALZ para su uso como diana para terapias para tratar el cáncer
|
BR112015022529A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
meios de cultura de células e processos de produção de anticorpo
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
WO2014144791A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
EP3216804A3
(en)
|
2013-03-15 |
2017-12-20 |
AbbVie Biotechnology Ltd. |
Anti-cd25 antibodies and their uses
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
CA2904528C
(en)
|
2013-03-15 |
2021-01-19 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
TW201525001A
(zh)
|
2013-03-15 |
2015-07-01 |
Amgen Res Munich Gmbh |
包含n-端abp之單鏈結合分子
|
BR112015023086A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
ES2770976T3
(es)
|
2013-03-15 |
2020-07-06 |
Amgen Inc |
Anticuerpos PAC1 humanos
|
CN110951670A
(zh)
|
2013-03-15 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
US10160797B2
(en)
|
2013-03-15 |
2018-12-25 |
Sanofi Pasteur Biologics, Llc |
Antibodies against Clostridium difficile toxins and methods of using the same
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
EP2983710B1
(en)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
WO2014182676A2
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
US9989540B2
(en)
|
2013-05-10 |
2018-06-05 |
The Regents Of The University Of California |
Diagnostic and monitoring system for Huntington's disease
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
ES2692657T3
(es)
|
2013-05-30 |
2018-12-04 |
Kiniksa Pharmaceuticals, Ltd. |
Proteínas de enlace al antígeno del receptor de oncastatina
|
US10781259B2
(en)
|
2013-06-06 |
2020-09-22 |
Magenta Therapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
EP3632467B1
(en)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitors of complement factor h
|
JP2016521744A
(ja)
|
2013-06-13 |
2016-07-25 |
ファスト フォワード ファーマスーティカルズ ベー.フェー. |
追加化合物が胆汁酸、胆汁酸誘導体、tgr5受容体作動物質、fxr作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのcd40シグナル伝達阻害物質および追加化合物
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
SG10201710758PA
(en)
|
2013-07-09 |
2018-02-27 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
KR20160030936A
(ko)
|
2013-07-16 |
2016-03-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
WO2015010100A2
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
WO2015019286A1
(en)
|
2013-08-07 |
2015-02-12 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
KR20160039682A
(ko)
|
2013-08-07 |
2016-04-11 |
아스튜트 메디컬 인코포레이티드 |
생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정
|
AU2014306564B2
(en)
|
2013-08-14 |
2019-10-17 |
Stephane ANGERS |
Antibodies against frizzled proteins and methods of use thereof
|
WO2015026846A1
(en)
|
2013-08-19 |
2015-02-26 |
Biogen Idec Ma Inc. |
Control of protein glycosylation by culture medium supplementation and cell culture process parameters
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
TWI660738B
(zh)
|
2013-09-27 |
2019-06-01 |
建南德克公司 |
抗-pdl1抗體調配物
|
SG11201602236SA
(en)
|
2013-10-01 |
2016-04-28 |
Kymab Ltd |
Animal models and therapeutic molecules
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
AU2014331909B2
(en)
|
2013-10-10 |
2020-03-12 |
Beth Israel Deaconess Medical Center, Inc. |
TM4SF1 binding proteins and methods of using same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
CA3120508A1
(en)
|
2013-10-28 |
2015-05-07 |
Dots Technology Corp. |
Allergen detection
|
WO2015066450A1
(en)
|
2013-10-31 |
2015-05-07 |
Sanofi |
Specific anti-cd38 antibodies for treating human cancers
|
MX2016005834A
(es)
|
2013-11-06 |
2016-11-17 |
Astute Medical Inc |
Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CA2932767A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
EP3080161B1
(en)
|
2013-12-09 |
2021-03-24 |
New York University |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
US9944694B2
(en)
|
2013-12-13 |
2018-04-17 |
Rijksuniversiteit Groningen |
Antibodies against Staphylococcus aureus and uses therof
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
EP3680254A1
(en)
|
2013-12-17 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
JP6779785B2
(ja)
|
2013-12-19 |
2020-11-04 |
ノバルティス アーゲー |
ヒトメソテリンキメラ抗原受容体およびその使用
|
EP3083933A1
(en)
|
2013-12-20 |
2016-10-26 |
Biogen MA Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
CA2931113C
(en)
|
2013-12-20 |
2023-07-11 |
Genentech, Inc. |
Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
|
EP3087098B1
(en)
|
2013-12-24 |
2020-04-08 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3094352B1
(en)
|
2014-01-16 |
2020-09-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
DK3102197T3
(da)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened-mutant og fremgangsmåder til anvendelse deraf
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3925973A1
(en)
|
2014-03-14 |
2021-12-22 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
BR112016021572A2
(pt)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
|
WO2015148515A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
CN106414552B
(zh)
|
2014-03-25 |
2020-08-25 |
豪夫迈·罗氏有限公司 |
制备用于细胞培养基中的泊洛沙姆的方法
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
US20170198054A1
(en)
|
2014-05-21 |
2017-07-13 |
Dana-Farber Cancer Institute |
Methods for treating cancer with anti bip or anti mica antibodies
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
AU2015267047A1
(en)
|
2014-05-27 |
2017-01-05 |
Academia Sinica |
Anti-CD20 glycoantibodies and uses thereof
|
EP3904388A1
(en)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
SG11201609721WA
(en)
|
2014-05-28 |
2016-12-29 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
NZ727705A
(en)
|
2014-07-09 |
2023-12-22 |
Genentech Inc |
Ph adjustment to improve thaw recovery of cell banks
|
CN106460067A
(zh)
|
2014-07-14 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
诊断方法和用于治疗成胶质细胞瘤的组合物
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
WO2016011160A1
(en)
|
2014-07-15 |
2016-01-21 |
Genentech, Inc. |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
WO2016016859A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
SG10201913611QA
(en)
|
2014-08-08 |
2020-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
EP3183002B1
(en)
|
2014-08-21 |
2021-03-03 |
Walter Reed Army Institute of Research |
Monoclonal antibodies for treatment of microbial infections
|
MA40539A
(fr)
|
2014-09-02 |
2016-03-10 |
Immunogen Inc |
Procédés de formulation de compositions de conjugués anticorps-médicaments
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
US10934362B2
(en)
|
2014-09-15 |
2021-03-02 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
US20160081314A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
ES2900331T3
(es)
|
2014-10-15 |
2022-03-16 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
CA2964463C
(en)
|
2014-10-22 |
2024-02-13 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
WO2016069283A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in cart cells and uses thereof
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
WO2016069993A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding t cells
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
ES2819256T3
(es)
|
2014-11-05 |
2021-04-15 |
Genentech Inc |
Métodos para producir proteínas bicatenarias en bacterias
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
WO2016081423A1
(en)
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
RU2758608C2
(ru)
|
2014-11-19 |
2021-11-01 |
Конинклейке Филипс Н.В. |
Способ диагностики с использованием hnl
|
US10517898B2
(en)
|
2014-11-20 |
2019-12-31 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
BR112017012377A2
(pt)
|
2014-12-09 |
2018-04-24 |
Abbvie Inc |
conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
|
JP2018508463A
(ja)
|
2014-12-09 |
2018-03-29 |
アッヴィ・インコーポレイテッド |
低細胞透過性を有するBcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
EP3333191B1
(en)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
US10703813B2
(en)
|
2014-12-19 |
2020-07-07 |
Universite De Nantes |
Anti IL-34 antibodies
|
CA2972048C
(en)
|
2014-12-22 |
2023-03-07 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
AU2016209032A1
(en)
|
2015-01-23 |
2017-08-10 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
KR102620346B1
(ko)
|
2015-01-30 |
2024-01-02 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
JP7170394B2
(ja)
|
2015-01-31 |
2022-11-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
治療用分子のt細胞送達のための組成物および方法
|
EP3253784B1
(en)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2016219534B2
(en)
|
2015-02-09 |
2021-07-01 |
Massachusetts Institute Of Technology |
Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof
|
CA2977767A1
(en)
|
2015-02-26 |
2016-09-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
RU2725221C2
(ru)
|
2015-03-03 |
2020-06-30 |
Кимаб Лимитед |
Антитела, их применение и способы применения
|
EP3265483B1
(en)
|
2015-03-06 |
2019-12-11 |
CSL Behring Lengnau AG |
Modified von willebrand factor having improved half-life
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
ES2721781T3
(es)
|
2015-03-25 |
2019-08-05 |
Alexion Pharma Inc |
Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
|
US20180074077A1
(en)
|
2015-03-25 |
2018-03-15 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
AU2016243052C1
(en)
*
|
2015-04-03 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of B-cells
|
RU2732628C2
(ru)
|
2015-04-06 |
2020-09-21 |
Регенерон Фармасьютикалз, Инк. |
Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
|
EA201792221A1
(ru)
|
2015-04-07 |
2018-08-31 |
ЭЛЕКТОР ЭлЭлСи |
Антитела против сортилина и способы их применения
|
US10849992B1
(en)
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
CA2982682A1
(en)
|
2015-04-17 |
2016-10-20 |
Amgen Research (Munich) Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
US10259882B2
(en)
|
2015-05-07 |
2019-04-16 |
Agenus Inc. |
Anti-OX40 antibodies
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
RS61152B1
(sr)
|
2015-05-12 |
2020-12-31 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
US10906982B2
(en)
|
2015-05-15 |
2021-02-02 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor 2 antibodies
|
JP7028765B2
(ja)
|
2015-05-22 |
2022-03-02 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
JP6518917B2
(ja)
|
2015-05-29 |
2019-05-29 |
アッヴィ・インコーポレイテッド |
抗cd40抗体およびその使用
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
CA3026154A1
(en)
|
2015-06-03 |
2016-12-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
AU2016276981B2
(en)
|
2015-06-12 |
2022-10-06 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
CN116327953A
(zh)
|
2015-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
US11009509B2
(en)
|
2015-06-24 |
2021-05-18 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
US10253101B2
(en)
|
2015-08-06 |
2019-04-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2995838A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
CN117491623A
(zh)
|
2015-08-20 |
2024-02-02 |
豪夫迈·罗氏有限公司 |
使用聚乙二醇化分析物特异性结合剂的基于颗粒的免疫测定法
|
EP3340786A4
(en)
|
2015-08-24 |
2019-03-13 |
Trianni, Inc. |
ENHANCED PRODUCTION OF IMMUNOGLOBULINS
|
WO2017040344A2
(en)
|
2015-08-28 |
2017-03-09 |
Amunix Operating Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
CA2996059A1
(en)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
US20180282415A1
(en)
|
2015-09-30 |
2018-10-04 |
Merck Patent Gmbh |
Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
|
KR20180068999A
(ko)
|
2015-10-06 |
2018-06-22 |
알렉터 엘엘씨 |
항-trem2 항체 및 그의 사용방법
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
WO2017075432A2
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
TW201720459A
(zh)
|
2015-11-02 |
2017-06-16 |
妮翠斯製藥公司 |
Ntn1中和劑與抑制後生控制之藥物之組合治療
|
CA3003759A1
(en)
|
2015-11-03 |
2017-05-11 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
JP7066613B2
(ja)
|
2015-11-12 |
2022-05-13 |
シージェン インコーポレイテッド |
グリカン相互作用化合物および使用方法
|
WO2017091745A1
(en)
|
2015-11-25 |
2017-06-01 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
CA3006596A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
Anti-hulrrc15 antibody drug conjugates and methods for their use
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
KR20180086246A
(ko)
|
2015-12-02 |
2018-07-30 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
|
WO2017095939A1
(en)
|
2015-12-03 |
2017-06-08 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
MA44154A
(fr)
|
2015-12-23 |
2018-10-31 |
Amgen Inc |
Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
WO2017117311A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
WO2017114972A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating ovarian cancer
|
EP3397965A1
(en)
|
2015-12-31 |
2018-11-07 |
Syncerus S.à R.l. |
Compositions and methods for assessing the risk of cancer occurrence
|
AU2017204686B2
(en)
|
2015-12-31 |
2020-04-30 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating esophageal cancer
|
CN108700588A
(zh)
|
2015-12-31 |
2018-10-23 |
普莱戈斯瑞恩癌症有限责任公司 |
用于检测和治疗胃癌的组合物和方法
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
PE20181536A1
(es)
|
2016-02-03 |
2018-09-26 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecificos para bcma y cd3 que se ligan a celulas t
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
CN109069626A
(zh)
|
2016-02-12 |
2018-12-21 |
詹森药业有限公司 |
抗-vista(b7h5)抗体
|
CA3015528A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
CN109071669A
(zh)
|
2016-03-07 |
2018-12-21 |
查尔斯顿制药有限责任公司 |
抗核仁素抗体
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
JP6430025B2
(ja)
|
2016-03-15 |
2018-11-28 |
中外製薬株式会社 |
Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
WO2017158084A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
HUE052869T2
(hu)
|
2016-03-17 |
2021-05-28 |
Tillotts Pharma Ag |
TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
|
IL261261B2
(en)
|
2016-03-17 |
2024-04-01 |
Numab Therapeutics AG |
Antibodies against TNF-ALPHA and their functional fragments
|
EP3219726B1
(en)
|
2016-03-17 |
2020-12-02 |
Tillotts Pharma AG |
Anti-tnf alpha-antibodies and functional fragments thereof
|
JP6978427B2
(ja)
|
2016-03-17 |
2021-12-08 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
抗TNFα抗体とその機能性フラグメント
|
KR20220004226A
(ko)
|
2016-03-22 |
2022-01-11 |
바이오노믹스 리미티드 |
항-lgr5 단클론성 항체의 투여
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
BR112018070097A2
(pt)
|
2016-03-29 |
2019-02-12 |
Obi Pharma, Inc. |
anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
MA44510A
(fr)
|
2016-03-29 |
2021-03-31 |
Janssen Biotech Inc |
Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3443350B1
(en)
|
2016-04-15 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
WO2017196902A2
(en)
|
2016-05-10 |
2017-11-16 |
Genentech, Inc. |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
ES2864150T3
(es)
|
2016-05-17 |
2021-10-13 |
Abbvie Biotherapeutics Inc |
Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
|
CN109415441B
(zh)
|
2016-05-24 |
2023-04-07 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
RU2018145184A
(ru)
|
2016-05-26 |
2020-06-26 |
Мерк Патент Гмбх |
Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
PT3464361T
(pt)
|
2016-05-27 |
2021-12-27 |
Abbvie Biotherapeutics Inc |
Anticorpos anti-cd40 e suas utilizações
|
KR20230091191A
(ko)
|
2016-05-27 |
2023-06-22 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
SG10201914014XA
(en)
|
2016-06-03 |
2020-03-30 |
Regeneron Pharma |
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
|
TW202304996A
(zh)
|
2016-06-08 |
2023-02-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
MX2018015584A
(es)
|
2016-06-13 |
2019-09-18 |
I Mab |
Anticuerpos anti-pd-l1 y usos de los mismos.
|
BR112018075032A2
(pt)
|
2016-06-15 |
2019-03-26 |
Icahn School Of Medicine At Mount Sinai |
proteínas de hemaglutinina do vírus influenza e seus uso
|
WO2018007999A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CN115925780A
(zh)
|
2016-07-22 |
2023-04-07 |
美国安进公司 |
含有Fc的蛋白的纯化方法
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
EP3490600A1
(en)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
JP2019524820A
(ja)
|
2016-08-12 |
2019-09-05 |
ジェネンテック, インコーポレイテッド |
Mek阻害剤、pd−1軸阻害剤及びvegf阻害剤での組合せ療法
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
UA124631C2
(uk)
|
2016-09-14 |
2021-10-20 |
Еббві Байотерапьютікс Інк. |
Антитіло до pd-1
|
CA3036509C
(en)
|
2016-09-19 |
2022-10-25 |
I-Mab |
Anti-gm-csf antibodies and uses thereof
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
RU2759334C2
(ru)
|
2016-09-21 |
2021-11-12 |
Нексткьюр, Инк. |
Антитела против siglec-15 и способы их применения
|
WO2018064255A2
(en)
|
2016-09-28 |
2018-04-05 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
JP2019534251A
(ja)
|
2016-09-29 |
2019-11-28 |
ジェネンテック, インコーポレイテッド |
Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法
|
EP3519049A4
(en)
|
2016-09-30 |
2020-05-27 |
Janssen Biotech, Inc. |
SAFE AND EFFICIENT METHOD FOR TREATING PSORIASIS WITH ANTI-IL23-SPECIFIC ANTIBODY
|
AU2017339809B2
(en)
|
2016-10-03 |
2022-02-17 |
Abbott Laboratories |
Improved methods of assessing UCH-L1 status in patient samples
|
JP2019530704A
(ja)
|
2016-10-06 |
2019-10-24 |
ファイザー・インコーポレイテッド |
がんの処置のためのアベルマブの投与レジメン
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
MA46529A
(fr)
|
2016-10-11 |
2019-08-21 |
Agenus Inc |
Anticorps anti-lag-3 et leurs procédés d'utilisation
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
US20190263926A1
(en)
|
2016-10-28 |
2019-08-29 |
Astute Medical, Inc. |
Use of Antibodies to TIMP-2 for the Improvement of Renal Function
|
US20200261470A1
(en)
|
2016-11-02 |
2020-08-20 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
WO2018087276A1
(en)
|
2016-11-10 |
2018-05-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Or10h1 modulators and uses thereof
|
EP3538555A1
(en)
|
2016-11-14 |
2019-09-18 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
MA50948A
(fr)
|
2016-12-07 |
2020-10-14 |
Agenus Inc |
Anticorps et procédés d'utilisation de ceux-ci
|
IL266918B2
(en)
|
2016-12-07 |
2024-03-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
AU2017377036B2
(en)
|
2016-12-15 |
2022-06-23 |
Abbvie Biotherapeutics Inc. |
Anti-OX40 antibodies and their uses
|
WO2018122205A2
(en)
|
2016-12-27 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
EP3562841A1
(en)
|
2016-12-27 |
2019-11-06 |
H. Hoffnabb-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
CN110088129A
(zh)
|
2016-12-27 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
新的生物素特异性单克隆抗体及其用途
|
EA039433B1
(ru)
|
2017-01-05 |
2022-01-27 |
Нетрис Фарма |
Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
WO2018133842A1
(zh)
|
2017-01-20 |
2018-07-26 |
大有华夏生物医药集团有限公司 |
人程序性死亡受体pd-1的单克隆抗体及其片段
|
KR20200108915A
(ko)
|
2017-01-24 |
2020-09-21 |
아이-맵 바이오파마 유에스 리미티드 |
항-cd73 항체 및 이것의 사용
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
EP3574012A1
(en)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
WO2018140121A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
JP7068323B2
(ja)
|
2017-02-02 |
2022-05-16 |
エフ.ホフマン-ラ ロシュ アーゲー |
少なくとも2種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
US10093731B2
(en)
|
2017-02-24 |
2018-10-09 |
Kindred Biosciences, Inc. |
Anti-IL31 antibodies for veterinary use
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
EP3601367A4
(en)
|
2017-03-30 |
2020-09-16 |
The University of Queensland |
CHEMERICAL MOLECULES AND ASSOCIATED USES
|
WO2018178363A1
(en)
|
2017-03-30 |
2018-10-04 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
|
CN110662967A
(zh)
|
2017-03-30 |
2020-01-07 |
Ecs前胃泌素股份有限公司 |
用于检测肺癌的组合物和方法
|
RU2765997C2
(ru)
|
2017-03-30 |
2022-02-07 |
Мерк Патент Гмбх |
Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
|
JP7315466B2
(ja)
|
2017-04-05 |
2023-07-26 |
アスチュート メディカル,インコーポレイテッド |
生体試料中において改善した性能を有する、timp2に関するアッセイ
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
MX2019012223A
(es)
|
2017-04-13 |
2019-12-09 |
Agenus Inc |
Anticuerpos anti-cd137 y metodos de uso de los mismos.
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
MA50958A
(fr)
|
2017-04-21 |
2020-10-14 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
BR112019022108A2
(pt)
|
2017-04-22 |
2020-05-12 |
Immunomic Therapeutics, Inc. |
Construções de lamp aprimoradas
|
EP3615052B1
(en)
|
2017-04-27 |
2023-01-25 |
The University of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
CA3053410A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
PL3618863T3
(pl)
|
2017-05-01 |
2023-11-06 |
Agenus Inc. |
Przeciwciała anty- tigit i sposoby ich zastosowania
|
IL297073B2
(en)
|
2017-05-02 |
2023-12-01 |
Immunomic Therapeutics Inc |
LAMP constructs containing cancer antigens
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
US10914729B2
(en)
|
2017-05-22 |
2021-02-09 |
The Trustees Of Princeton University |
Methods for detecting protein binding sequences and tagging nucleic acids
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
JP7416625B2
(ja)
|
2017-05-25 |
2024-01-17 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
|
JP7269182B2
(ja)
|
2017-05-30 |
2023-05-08 |
アボット・ラボラトリーズ |
心臓トロポニンi及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
|
EP3630835A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
WO2018237097A1
(en)
|
2017-06-20 |
2018-12-27 |
Amgen Inc. |
METHOD OF TREATING OR REDUCING METABOLIC DISORDERS USING GASTRIC INHIBITING PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
MA48241A1
(fr)
|
2017-07-14 |
2021-03-31 |
Pfizer |
Anticorps dirigés contre madcam
|
US11674962B2
(en)
|
2017-07-21 |
2023-06-13 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3625250B1
(en)
|
2017-07-21 |
2021-04-14 |
Trianni, Inc. |
Single chain vh and heavy chain antibodies
|
WO2020159504A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
WO2019023460A1
(en)
|
2017-07-27 |
2019-01-31 |
Nomocan Pharmaceuticals Llc |
ANTIBODIES AGAINST M (H) DM2 / 4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER
|
PT3661954T
(pt)
|
2017-08-03 |
2022-04-14 |
Amgen Inc |
Muteínas de interleuquina-21 e métodos de tratamento
|
EP3601358B1
(en)
|
2017-08-03 |
2023-05-17 |
Alector LLC |
Anti-trem2 antibodies and methods of use thereof
|
CR20190486A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
MX2020001327A
(es)
|
2017-08-04 |
2020-03-20 |
Amgen Inc |
Metodo de conjugacion de cys-acm.
|
KR20200038996A
(ko)
|
2017-08-21 |
2020-04-14 |
아다진 인크. |
동적 인간 중쇄 항체 라이브러리
|
BR112020003459A2
(pt)
|
2017-08-21 |
2020-08-25 |
Adagene Inc. |
bibliotecas, animal não humano, fago, cadeia leve de anticorpo, anticorpos, métodos para preparar uma biblioteca, para produzir uma biblioteca de anticorpos e para gerar um anticorpo biespecífico e kit
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
BR112020005737A2
(pt)
|
2017-09-22 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo recombinante multivalente e uso do mesmo, kit e método para detectar um antígeno
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
EP3694890A4
(en)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
LIGHT CHAIN ANTIBODY FUSION PROTEIN WITH VEGFR
|
US11826414B2
(en)
|
2017-10-23 |
2023-11-28 |
Cz Biohub Sf, Llc |
Measurement of afucosylated IgG Fc glycans and related vaccination methods
|
JP7403164B2
(ja)
|
2017-10-26 |
2023-12-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
虚血性再灌流障害を治療するための酸化特異的エピトープの阻害
|
DK3476942T3
(da)
|
2017-10-27 |
2022-04-19 |
Trianni Inc |
Lange kimlinje-dh-gener og antistoffer med lang hcdr3
|
WO2019087115A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
TW201922294A
(zh)
|
2017-10-31 |
2019-06-16 |
美商伊繆諾金公司 |
抗體-藥物結合物與阿糖胞苷之組合治療
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
CA3083345A1
(en)
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
US11046758B2
(en)
|
2017-12-05 |
2021-06-29 |
Progastrine Et Cancers S.À R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
JP7430636B2
(ja)
*
|
2017-12-05 |
2024-02-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
|
SG11202004913TA
(en)
|
2017-12-06 |
2020-06-29 |
Magenta Therapeutics Inc |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
AU2018378971A1
(en)
|
2017-12-09 |
2020-01-02 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
|
CN110892266A
(zh)
|
2017-12-09 |
2020-03-17 |
雅培实验室 |
使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
|
WO2019118426A1
(en)
|
2017-12-11 |
2019-06-20 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
EP4295915A2
(en)
|
2017-12-20 |
2023-12-27 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
CN112041341A
(zh)
|
2017-12-28 |
2020-12-04 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
KR20200110362A
(ko)
|
2018-01-12 |
2020-09-23 |
암젠 인크 |
Pac1 항체 및 이의 용도
|
SG11202005605SA
(en)
|
2018-01-12 |
2020-07-29 |
Amgen Inc |
Anti-pd-1 antibodies and methods of treatment
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-1に対する単一ドメイン抗体及びその変異体
|
JP2021512142A
(ja)
|
2018-01-25 |
2021-05-13 |
エイシーエム バイオラブズ プライベート リミテッド |
可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
|
WO2019145537A1
(en)
|
2018-01-26 |
2019-08-01 |
Ecs-Progastrin Sa |
Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
KR20200144541A
(ko)
|
2018-02-27 |
2020-12-29 |
이씨에스-프로가스트린 에스에이 |
면역치료요법용 생체표지자로서 프로가스트린
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
IL276896B1
(en)
|
2018-03-05 |
2024-02-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
EP3765499A1
(en)
|
2018-03-12 |
2021-01-20 |
Zoetis Services LLC |
Anti-ngf antibodies and methods thereof
|
CN112166123B
(zh)
|
2018-03-14 |
2022-09-30 |
北京轩义医药科技有限公司 |
抗紧密连接蛋白18.2抗体
|
US11292850B2
(en)
|
2018-03-21 |
2022-04-05 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein α and methods of use
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
MX2020009989A
(es)
|
2018-03-24 |
2020-10-14 |
Regeneron Pharma |
Animales no humanos geneticamente modificados para generar anticuerpos terapeuticos contra complejos peptidos-mhc, metodos de elaboracion y usos de estos.
|
CN116420679A
(zh)
|
2018-03-26 |
2023-07-14 |
瑞泽恩制药公司 |
用于测试治疗剂的人源化啮齿动物
|
JP2021519443A
(ja)
|
2018-03-26 |
2021-08-10 |
グリカノスティックス エス・アール・オーGlycanostics S.R.O. |
タンパク質糖鎖プロファイリングの手段及び方法
|
WO2019197651A1
(en)
|
2018-04-12 |
2019-10-17 |
Mediapharma S.R.L. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
JP2021522298A
(ja)
|
2018-05-04 |
2021-08-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
癌治療のためのPD−1/PD−L1、TGFβおよびDNA−PKの同時阻害
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
CA3100004A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs comprising allergens
|
BR112020023844A2
(pt)
|
2018-05-25 |
2021-04-13 |
Alector Llc |
Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
|
WO2019236739A1
(en)
|
2018-06-05 |
2019-12-12 |
Amgen Inc. |
Modulating antibody dependent cellular phagocytosis
|
MA52764A
(fr)
|
2018-06-08 |
2021-04-28 |
Alector Llc |
Anticorps anti-siglec-7 et leurs méthodes d'utilisation
|
DK3629720T3
(da)
|
2018-06-14 |
2022-03-07 |
Regeneron Pharma |
Ikke-humane dyr, der er i stand til at omarrangere DH-DH i immunoglobulin-tungkæde-kodningssekvenser
|
CA3104291A1
(en)
|
2018-06-21 |
2019-12-26 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
MX2020014091A
(es)
|
2018-06-23 |
2021-05-27 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
EP3841124A4
(en)
|
2018-06-29 |
2022-03-23 |
ApitBio, Inc. |
ANTI-L1CAM ANTIBODIES AND THEIR USES
|
HUE061841T2
(hu)
|
2018-07-13 |
2023-08-28 |
Alector Llc |
Anti-sortilin antitestek és felhasználásuk módszerei
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
US20230243836A1
(en)
|
2018-07-20 |
2023-08-03 |
Pierre Fabre Medicament |
Receptor for vista
|
EP3827020A1
(en)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
CA3106535A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与
|
BR112021002032A2
(pt)
|
2018-08-03 |
2021-07-20 |
Amgen Research (Munich) Gmbh |
construtos de anticorpos para cldn18.2 e cd3
|
AR115925A1
(es)
|
2018-08-08 |
2021-03-10 |
Genentech Inc |
Uso de derivados de triptófano y l-metionina para formulación de proteínas
|
BR112021003436A2
(pt)
|
2018-08-27 |
2021-05-18 |
Affimed Gmbh |
células nk criopreservadas pré-carregadas com uma construção de anticorpo
|
EP3850006A1
(en)
|
2018-09-11 |
2021-07-21 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
CN112996539A
(zh)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
JP7359845B2
(ja)
|
2018-09-24 |
2023-10-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
|
BR112021004935A2
(pt)
|
2018-09-26 |
2021-06-01 |
Merck Patent Gmbh |
combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
|
US11505614B2
(en)
|
2018-09-28 |
2022-11-22 |
Amgen Inc. |
Antibodies binding to soluble BCMA
|
EP3860713A2
(en)
|
2018-10-03 |
2021-08-11 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
US20210369705A1
(en)
|
2018-10-15 |
2021-12-02 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
AU2019363713A1
(en)
|
2018-10-24 |
2021-05-27 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Vaccination and antibody generation platform
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
MX2021004819A
(es)
|
2018-11-02 |
2021-06-08 |
Annexon Inc |
Composiciones y metodos para tratar lesiones cerebrales.
|
CN113260626A
(zh)
|
2018-11-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
WO2020099533A1
(en)
|
2018-11-16 |
2020-05-22 |
F. Hoffmann-La Roche Ag |
Streptavidin-coated solid phases with a member of a binding pair
|
KR20210093973A
(ko)
|
2018-11-20 |
2021-07-28 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020118293A2
(en)
|
2018-12-07 |
2020-06-11 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
JP2022514561A
(ja)
|
2018-12-18 |
2022-02-14 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体でループスを治療する安全かつ有効な方法
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
KR20210116540A
(ko)
|
2019-01-15 |
2021-09-27 |
얀센 바이오테크 인코포레이티드 |
소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
|
CA3127748A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
JP2022523475A
(ja)
|
2019-01-23 |
2022-04-25 |
ジェネンテック, インコーポレイテッド |
真核宿主細胞において多量体タンパク質を産生する方法
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US11639388B2
(en)
|
2019-02-22 |
2023-05-02 |
Wuhan Yzy Biopharma Co., Ltd. |
CD3 antigen binding fragment and application thereof
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
EA202192505A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
EP3938390A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20210141990A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
|
KR102588292B1
(ko)
|
2019-03-15 |
2023-10-11 |
카티전 테라퓨틱스, 인코포레이티드 |
항-bcma 키메라 항원 수용체
|
MX2021011328A
(es)
|
2019-03-18 |
2021-12-10 |
Janssen Biotech Inc |
Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
|
JP2022527297A
(ja)
|
2019-03-27 |
2022-06-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Tn-MUC1キメラ抗原受容体(CAR)T細胞療法
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
AU2020263959A1
(en)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
MX2021014534A
(es)
|
2019-05-30 |
2022-02-11 |
Amgen Inc |
Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
|
MA56015A
(fr)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech Inc |
Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
|
CN114173873A
(zh)
|
2019-06-03 |
2022-03-11 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
AU2020289474A1
(en)
|
2019-06-07 |
2021-12-23 |
Amgen Inc. |
Bispecific binding constructs
|
US20220259547A1
(en)
|
2019-06-13 |
2022-08-18 |
Amgeng Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
WO2020264384A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
JP2022538886A
(ja)
|
2019-07-01 |
2022-09-06 |
トリアニ・インコーポレイテッド |
トランスジェニック哺乳動物およびその使用法
|
US20220369609A1
(en)
|
2019-07-01 |
2022-11-24 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
EP3993876A1
(en)
|
2019-07-01 |
2022-05-11 |
Tonix Pharma Limited |
Anti-cd154 antibodies and uses thereof
|
US20220372138A1
(en)
|
2019-07-05 |
2022-11-24 |
Iomx Therapeutics Ag |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
EP3763737A1
(en)
|
2019-07-12 |
2021-01-13 |
Eberhard Karls Universität Tübingen |
Binding compounds of penicillin binding protein 2 a
|
AU2020323901A1
(en)
|
2019-07-26 |
2022-02-24 |
Amgen Inc. |
Anti-IL13 antigen binding proteins
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
EP3785536B1
(en)
|
2019-08-28 |
2022-01-26 |
Trianni, Inc. |
Adam6 knockin mice
|
KR20220053007A
(ko)
|
2019-08-30 |
2022-04-28 |
아게누스 인코포레이티드 |
항-cd96 항체 및 이의 사용 방법
|
WO2021043206A1
(zh)
|
2019-09-03 |
2021-03-11 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
EP4028416A1
(en)
|
2019-09-10 |
2022-07-20 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
MX2022002963A
(es)
|
2019-09-12 |
2022-04-06 |
Genentech Inc |
Composiciones y metodos para tratar nefritis lupica.
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
KR20220083773A
(ko)
|
2019-10-18 |
2022-06-20 |
이뮤노믹 쎄라퓨틱스, 인크. |
암 항원을 포함하는 개선된 lamp 구축물
|
TW202128160A
(zh)
|
2019-10-18 |
2021-08-01 |
美國加利福尼亞大學董事會 |
用於治療病原性血管病症之方法及組合物
|
US20230044248A1
(en)
|
2019-11-01 |
2023-02-09 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
EP4051298A1
(en)
|
2019-11-01 |
2022-09-07 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progentor cells
|
BR112022008295A2
(pt)
|
2019-11-05 |
2022-07-26 |
Merck Patent Gmbh |
Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
|
EP4055388A1
(en)
|
2019-11-06 |
2022-09-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CA3160482A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
AU2020386005A1
(en)
|
2019-11-19 |
2022-05-26 |
Amgen Inc. |
Novel multispecific antibody format
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
IL293330A
(en)
|
2019-12-02 |
2022-07-01 |
Regeneron Pharma |
mhc ii peptide protein structures and uses thereof
|
EP3986937A1
(en)
|
2019-12-05 |
2022-04-27 |
Alector LLC |
Methods of use of anti-trem2 antibodies
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
KR20220113414A
(ko)
|
2019-12-09 |
2022-08-12 |
제넨테크, 인크. |
항-pd-l1 항체 제제
|
CN115066437A
(zh)
|
2019-12-12 |
2022-09-16 |
艾利妥 |
使用抗cd33抗体的方法
|
US11926672B2
(en)
|
2019-12-20 |
2024-03-12 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
CA3160927A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
CA3164037A1
(en)
|
2020-01-08 |
2021-07-15 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
IL294859A
(en)
|
2020-01-31 |
2022-09-01 |
Genentech Inc |
Methods for induction of neoepitope-specific t cells with spindle-binding antagonist 1-pd and RNA vaccine
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
CN115768794A
(zh)
|
2020-02-24 |
2023-03-07 |
艾利妥 |
抗trem2抗体的使用方法
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
EP4118112A1
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
EP4118113A1
(en)
|
2020-03-12 |
2023-01-18 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4130035A1
(en)
|
2020-03-31 |
2023-02-08 |
Bio-Thera Solutions, Ltd. |
Antibody and fusion protein for treating coronaviruses and use thereof
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック, インコーポレイテッド |
がんに対する治療方法及び診断方法
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
JP2023523334A
(ja)
|
2020-04-27 |
2023-06-02 |
マジェンタ セラピューティクス インコーポレイテッド |
in vivoで造血幹細胞及び造血前駆細胞を形質導入するための方法及び組成物
|
US20230167198A1
(en)
|
2020-04-27 |
2023-06-01 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
EP4157874A2
(en)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
US20230203198A1
(en)
|
2020-06-04 |
2023-06-29 |
Amgen Inc. |
Bispecific binding constructs
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
EP4168118A1
(en)
|
2020-06-18 |
2023-04-26 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
EP4172184A2
(en)
|
2020-06-26 |
2023-05-03 |
Amgen Inc. |
Il-10 muteins and fusion proteins thereof
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
US20240010720A1
(en)
|
2020-07-06 |
2024-01-11 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Tigit及cd112r阻斷
|
AU2021311743A1
(en)
|
2020-07-24 |
2023-02-16 |
Amgen Inc. |
Immunogens derived from SARS-CoV-2 spike protein
|
AR123085A1
(es)
|
2020-07-31 |
2022-10-26 |
Genentech Inc |
FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
TW202214698A
(zh)
|
2020-08-07 |
2022-04-16 |
大陸商百奧泰生物製藥股份有限公司 |
抗pd-l1抗體及其應用
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
MX2023002125A
(es)
|
2020-08-20 |
2023-04-26 |
Amgen Inc |
Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
CN116113707A
(zh)
|
2020-08-31 |
2023-05-12 |
基因泰克公司 |
用于产生抗体的方法
|
CN116390750A
(zh)
|
2020-09-04 |
2023-07-04 |
罗格斯新泽西州立大学 |
SARS-CoV-2疫苗和抗体
|
TW202229328A
(zh)
|
2020-09-11 |
2022-08-01 |
美商再生元醫藥公司 |
抗原特異性抗體之鑑定及產生
|
JP2023541456A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
がん治療用キメラ抗原受容体
|
AU2021358033A1
(en)
|
2020-10-07 |
2023-05-04 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
IL300314A
(en)
|
2020-10-08 |
2023-04-01 |
Affimed Gmbh |
Coupling materials with triple specificity
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
CA3196557A1
(en)
|
2020-11-02 |
2022-05-05 |
Ada SALA-HOJMAN |
Combination treatment of cancer
|
WO2022090455A1
(en)
|
2020-11-02 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Sars-cov-2 nucleocapsid antibodies
|
JP2023550900A
(ja)
|
2020-11-02 |
2023-12-06 |
アレス トレーディング ソシエテ アノニム |
がんの組み合わせ治療
|
EP3992205A1
(en)
|
2020-11-03 |
2022-05-04 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Sars coronavirus-2 spike protein binding compounds
|
WO2022096536A1
(en)
|
2020-11-03 |
2022-05-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
CA3200317A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
EP4240770A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
AU2021375733A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
CN114437227A
(zh)
|
2020-11-06 |
2022-05-06 |
百奥泰生物制药股份有限公司 |
双特异抗体及其应用
|
JP2023548595A
(ja)
|
2020-11-10 |
2023-11-17 |
アムジエン・インコーポレーテツド |
多重特異性抗原結合ドメインの新規のリンカー
|
EP4253415A1
(en)
|
2020-11-12 |
2023-10-04 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Antibody and preparation method therefor
|
WO2022106205A1
(en)
|
2020-11-18 |
2022-05-27 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Corona virus spike protein binding compounds
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
JP2023553384A
(ja)
|
2020-12-03 |
2023-12-21 |
アムジエン・インコーポレーテツド |
複数の結合ドメインを有する免疫グロブリン構築物
|
US20240023526A1
(en)
|
2020-12-09 |
2024-01-25 |
Trianni, Inc. |
Heavy chain-only antibodies
|
CA3199879A1
(en)
|
2020-12-16 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
WO2022140219A1
(en)
|
2020-12-23 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4274587A1
(en)
|
2021-01-06 |
2023-11-15 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
AU2022212599A1
(en)
|
2021-01-28 |
2023-08-17 |
Universität Ulm |
Method and means for modulating b-cell mediated immune responses
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308694A1
(en)
|
2021-03-16 |
2024-01-24 |
Magenta Therapeutics, Inc. |
Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
JP2024513246A
(ja)
|
2021-04-09 |
2024-03-22 |
ジェネンテック, インコーポレイテッド |
Raf阻害剤及びpd-1軸阻害剤を用いた併用治療
|
JP2024515301A
(ja)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
KR20240005823A
(ko)
|
2021-05-04 |
2024-01-12 |
리제너론 파아마슈티컬스, 인크. |
다중특이적 fgf21 수용체 효능제 및 그의 용도
|
IL307638A
(en)
|
2021-05-05 |
2023-12-01 |
Trianni Inc |
Transgenic rodents expressing horse-rodent chimeric antibodies and methods of using them
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
WO2022235940A1
(en)
|
2021-05-06 |
2022-11-10 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
CA3220380A1
(en)
|
2021-06-07 |
2022-12-15 |
Rinat ZAYNAGETDINOV |
Combination treatment of cancer
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
WO2022272018A1
(en)
|
2021-06-25 |
2022-12-29 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
WO2023281462A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20240034215A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
|
KR20240032991A
(ko)
|
2021-07-09 |
2024-03-12 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 생성을 위한 제조 방법
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Double structure antibodies
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
AU2022328390A1
(en)
|
2021-08-10 |
2024-03-21 |
Adimab, Llc |
Anti-gdf15 antibodies, compositions and uses thereof
|
IL310862A
(en)
|
2021-08-16 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Antibodies against FLT3, chimeric antigen receptors, chimeric antigen receptor T cells and methods of use
|
IL310861A
(en)
|
2021-08-17 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Bispecific antibodies against FLT3 and CD3 and methods of use
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
CA3230934A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023056430A1
(en)
|
2021-10-01 |
2023-04-06 |
Abcellera Biologics Inc. |
Transgenic rodents for cell line identification and enrichment
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023072904A1
(en)
|
2021-10-26 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Monoclonal antibodies specific for sars-cov-2 rbd
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086815A1
(en)
|
2021-11-10 |
2023-05-19 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111168A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
A novel antibody for detection of amyloid beta 42 (aβ42)
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
WO2023139292A1
(en)
|
2022-01-24 |
2023-07-27 |
Cambridge Enterprise Limited |
Tau therapy
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|